The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales

SOYSAL, Pinar; ISIK, Ahmet Turan; kocyigit, suleyman emre; DOKUZLAR, Özge; AYDIN, ALI EKREM; Koc Okudur, Saadet

doi:10.14744/nci.2020.17136

The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales

Saadet Koc OKUDUR, (Manisa Devlet Hastanesi Geriatrik Tıp Kliniği, Manisa, Türkiye)

Özge DOKUZLAR, (Dokuz Eylül Üniversitesi Tıp Fakültesi Geriatrik Tıp Anabilim Dalı, İzmir, Türkiye)

Ali Ekrem AYDIN, (Sivas Numune Hastanesi, Geriatrik Tıp Kliniği, Sivas, Türkiye)

Süleyman Emre KOÇYİĞİT, (İzmir Tepecik Eğitim ve Araştırma Hastanesi, Geriatrik Tıp Kliniği, İzmir, Türkiye)

Pınar SOYSAL, (Bezmialem Vakıf Üniversitesi Tıp Fakültesi Geriatrik Tıp Anabilim Dalı, İstanbul, Türkiye)

Ahmet Turan IŞIK (Dokuz Eylül Üniversitesi Tıp Fakültesi Geriatrik Tıp Anabilim Dalı, İzmir, Türkiye)

İstanbul Kuzey Klinikleri

8 0

Yıl: 2021 Cilt: 8 Sayı: 2 Sayfa Aralığı: 139 - 144 Metin Dili: İngilizce DOI: 10.14744/nci.2020.17136 İndeks Tarihi: 09-05-2021

The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales

Öz:

OBJECTIVE: Polypharmacy and anticholinergic burden are the indicators for the evaluation of the quality of pharmacotherapy in older adults. The aim of this study was to consider which anticholinergic burden scales are more related with polypharmacy among older patients.METHODS: Four hundred and twenty older adults were evaluated retrospectively in this cross-sectional study. The patient’s demographic data, comorbidities, the drugs, and number of drugs were recorded. Anticholinergic burden scales were calculated by a tool named anticholinergic burden calculator.RESULTS: The participants’ mean age was 73.08±8.71. The prevalence of polypharmacy was 32.14%. The highest relationship with polypharmacy was observed for drug burden index (DBI) (odds ratio 10.87, p<0.001).CONCLUSION: Our study demonstrated that polypharmacy and DBI scores were more related than other anticholinergic burden scales in older adults.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. United Nations. World population prospects. 2017 revision. Available at: https://population.un.org/wpp/Publications/Files/WPP2017_ KeyFindings.pdf. Accessed Feb 12, 2021.
2. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: single-center experience in Turkey between 2013 and 2017. Clin Interv Aging 2018;13:1899–905.
3. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging 2009;26:493–503.
4. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716–24.
5. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616–31.
6. Rudd KM, Raehl CL, Bond CA, Abbruscato TJ, Stenhouse AC. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy 2005;25:1592–601.
7. Wilson M, Mair A, Dreischulte T, Witham MD; NHS Scotland Model of Care Polypharmacy Working Group. Prescribing to fit the needs of older people-the NHS Scotland Polypharmacy Guidance, 2nd edition. J R Coll Physicians Edinb 2015;45:108–13.
8. Onder G, Landi F, Fusco D, Corsonello A, Tosato M, Battaglia M, et al. Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project. Drugs Aging 2014;31:33–45.
9. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc 2015;63:85–90.
10. Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009;30:87–92.
11. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;43:604–15.
12. Kumpula EK, Bell JS, Soini H, Pitkälä KH. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol 2011;51:256–63.
13. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:503–13.
14. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006;46:1481–6.
15. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008;4:311–20.
16. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008;56:1333–41.
17. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007;167:781–7.
18. Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging 2018;35:523–38.
19. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics 2013;13:17–24.
20. Unutmaz GD, Soysal P, Tuven B, Isik AT. Costs of medication in older patients: before and after comprehensive geriatric assessment. Clin Interv Aging 2018;13:607–13.
21. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62 Suppl 21:11–4.
22. Villalba-Moreno AM, Alfaro-Lara ER, Pérez-Guerrero MC, Nieto-Martín MD, Santos-Ramos B. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr 2016;62:1–8.
23. Campbell N, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc 2013;61:S142–3.
24. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry 2010;81:160–5.
25. Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, et al; AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord 2011;31:173–8.
26. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008;56:2203–10.
27. Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 2013;69:1485–96.
28. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006;332:455–9.
29. Villalba-Moreno Á, Alfaro-Lara ER, Sánchez-Fidalgo S, Nieto-Martín MD, Santos-Ramos B. Development of the anticholinergic burden calculator web tool. Farm Hosp 2017;41:647–8.
30. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014;13:57–65.
31. Best O, Gnjidic D, Hilmer SN, Naganathan V, McLachlan AJ. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J 2013;43:912–8.
32. Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: a cross-sectional analysis of data from The English Longitudinal Study of Ageing (ELSA). BMJ Open 2018;8:e020270.
33. Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract 2007;24:14–9.
34. Naples JG, Marcum ZA, Perera S, Gray SL, Newman AB, Simonsick EM, et al; Health, Aging and Body Composition Study. Concordance between Anticholinergic Burden Scales. J Am Geriatr Soc 2015;63:2120–4.
35. Pont LG, Nielen JT, McLachlan AJ, Gnjidic D, Chan L, Cumming RG, et al. Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures. Br J Clin Pharmacol 2015;80:1169–75.
36. Mayer T, Meid AD, Saum KU, Brenner H, Schöttker B, Seidling HM, et al. Comparison of nine instruments to calculate anticholinergic load in a large cohort of older outpatients: association with cognitive and functional decline, falls, and use of laxatives. Am J Geriatr Psychiatry 2017;25:531–40.
37. Park KH, Yang YM, Yoo JC, Choi EJ. Comparative analysis of anticholinergics prescribed to elderly patients at a Korean long-term care facility according to beers criteria 2003, 2012, and 2015 and Anticholinergic-Burden Rating Scales: A cross-sectional retrospective study. Clin Interv Aging 2019;14:1963–74.
38. Ong GJ, Page A, Caughey G, Johns S, Reeve E, Shakib S. Clinician agreement and influence of medication-related characteristics on assessment of polypharmacy. Pharmacol Res Perspect 2017;5:e00321

APA	Koc Okudur S, DOKUZLAR Ö, AYDIN A, kocyigit s, SOYSAL P, ISIK A (2021). The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. , 139 - 144. 10.14744/nci.2020.17136
Chicago	Koc Okudur Saadet,DOKUZLAR Özge,AYDIN ALI EKREM,kocyigit suleyman emre,SOYSAL Pinar,ISIK Ahmet Turan The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. (2021): 139 - 144. 10.14744/nci.2020.17136
MLA	Koc Okudur Saadet,DOKUZLAR Özge,AYDIN ALI EKREM,kocyigit suleyman emre,SOYSAL Pinar,ISIK Ahmet Turan The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. , 2021, ss.139 - 144. 10.14744/nci.2020.17136
AMA	Koc Okudur S,DOKUZLAR Ö,AYDIN A,kocyigit s,SOYSAL P,ISIK A The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. . 2021; 139 - 144. 10.14744/nci.2020.17136
Vancouver	Koc Okudur S,DOKUZLAR Ö,AYDIN A,kocyigit s,SOYSAL P,ISIK A The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. . 2021; 139 - 144. 10.14744/nci.2020.17136
IEEE	Koc Okudur S,DOKUZLAR Ö,AYDIN A,kocyigit s,SOYSAL P,ISIK A "The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales." , ss.139 - 144, 2021. 10.14744/nci.2020.17136
ISNAD	Koc Okudur, Saadet vd. "The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales". (2021), 139-144. https://doi.org/10.14744/nci.2020.17136

APA	Koc Okudur S, DOKUZLAR Ö, AYDIN A, kocyigit s, SOYSAL P, ISIK A (2021). The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. İstanbul Kuzey Klinikleri, 8(2), 139 - 144. 10.14744/nci.2020.17136
Chicago	Koc Okudur Saadet,DOKUZLAR Özge,AYDIN ALI EKREM,kocyigit suleyman emre,SOYSAL Pinar,ISIK Ahmet Turan The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. İstanbul Kuzey Klinikleri 8, no.2 (2021): 139 - 144. 10.14744/nci.2020.17136
MLA	Koc Okudur Saadet,DOKUZLAR Özge,AYDIN ALI EKREM,kocyigit suleyman emre,SOYSAL Pinar,ISIK Ahmet Turan The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. İstanbul Kuzey Klinikleri, vol.8, no.2, 2021, ss.139 - 144. 10.14744/nci.2020.17136
AMA	Koc Okudur S,DOKUZLAR Ö,AYDIN A,kocyigit s,SOYSAL P,ISIK A The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. İstanbul Kuzey Klinikleri. 2021; 8(2): 139 - 144. 10.14744/nci.2020.17136
Vancouver	Koc Okudur S,DOKUZLAR Ö,AYDIN A,kocyigit s,SOYSAL P,ISIK A The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales. İstanbul Kuzey Klinikleri. 2021; 8(2): 139 - 144. 10.14744/nci.2020.17136
IEEE	Koc Okudur S,DOKUZLAR Ö,AYDIN A,kocyigit s,SOYSAL P,ISIK A "The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales." İstanbul Kuzey Klinikleri, 8, ss.139 - 144, 2021. 10.14744/nci.2020.17136
ISNAD	Koc Okudur, Saadet vd. "The evaluation of relationship betweenpolypharmacy and anticholinergic burden scales". İstanbul Kuzey Klinikleri 8/2 (2021), 139-144. https://doi.org/10.14744/nci.2020.17136